Loading clinical trials...
Loading clinical trials...
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Conditions
Interventions
azacitidine
cytarabine
+2 more
Locations
1
United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Start Date
June 6, 2012
Primary Completion Date
August 16, 2019
Completion Date
August 16, 2019
Last Updated
May 15, 2020
NCT01822015
NCT00352365
NCT01235572
NCT01093586
NCT01872819
NCT00666588
Lead Sponsor
University of Chicago
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions